|
24 Mar 2020 |
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
|
|
23 Mar 2020 |
Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures
|
|
23 Mar 2020 |
Sorrento and Smartpharm to collaborate to develop novel gene-encoded antibody vaccine intended to protect against COVID-19
|
|
23 Mar 2020 |
AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
|
|
20 Mar 2020 |
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
|
|
19 Mar 2020 |
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
|
|
19 Mar 2020 |
Dragonfly Therapeutics Announces Multi-Target Expansion of its Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Therapeutic Candidates in the fields of Oncology, Infectious Disease, and Immune Disorders
|
|
19 Mar 2020 |
NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
|
|
18 Mar 2020 |
GEMoaB Announces Publication of Pre-Clinical Proof-of-Concept Data on UniCAR-modified Off-the-shelf Natural Killer Cells in 'Nature Scientific Reports'
|
|
18 Mar 2020 |
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
|
|
16 Mar 2020 |
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
|
|
13 Mar 2020 |
Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
|
|
13 Mar 2020 |
FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections
|
|
13 Mar 2020 |
Artugen Therapeutics Announces First Patient Dosed with ART24, Artugen’s First Clinical Product Candidate for Prevention of Recurrence of Clostridium Difficile Infection
|
|
11 Mar 2020 |
Notice of Capital and Business Alliance between Heartseed and MEDIPAL HOLDINGS
|
|
11 Mar 2020 |
Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities
|
|
11 Mar 2020 |
Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors
|
|
10 Mar 2020 |
Mesoblast to evaluate anti-inflammatory cell therapy remestemcel-L for treatment of COVID-19 lung disease
|
|
09 Mar 2020 |
GEMoaB Announces First Patient Apheresed in a Phase IA Study With Lead Product Candidate From Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias
|
|
05 Mar 2020 |
Dynacure Announces First Patient Dosed in Phase 1 / 2 'UNITE-CNM' Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)
|
|
04 Mar 2020 |
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
|
|
04 Mar 2020 |
EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance
|
|
04 Mar 2020 |
MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours
|
|
04 Mar 2020 |
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10
|
|
04 Mar 2020 |
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
|
